Almaral has made a significant venture capital investment in Genomill, a Finland-based health technology company at the forefront of cancer diagnostics. The investment from Almaral represents a bold and visionary commitment to the future of precision diagnostics.
Genomill advances cancer diagnostics by improving the performance and accessibility of liquid biopsies in healthcare on a global scale. Liquid biopsy is an advanced diagnostic method that allows the detection of cancer-derived DNA from any bodily fluid. However, there are still challenges to be addressed for its broader use.
‘Cancer is a global health issue but there’s still a journey ahead in terms of accessibility to liquid biopsies’, says Kalle Koskinen, CEO of Genomill.
‘We firmly believe that Geno1 technology can deliver low-cost, high-performing and scalable liquid biopsies – leading to the democratization of cancer diagnostics.’ Koskinen elaborates.
Almaral’s investment is exceptional, especially at a time when venture capitalists typically operate very cautiously.
‘We recognized an exceptional team and a brilliant innovation in Genomill. We want to actively participate in developing this into a global success story’, states Dr. Maria Severina, CEO of Almaral.
‘Almaral’s investment demonstrates that we are not a traditional venture capital company. Our approach is characterized by comprehensive and responsible investment, enabling a long-term perspective. The impending investment slump does not affect our strategy’, Severina explains.
Genomill democratizes cancer diagnostics
Genomill (Genomill Health Ltd.) is a highly innovative and pioneering technology startup focused on developing its patented Geno1 liquid biopsy technology. The company’s vision is to lead the transformation of precision diagnostics and make liquid biopsies accessible to more people across the world.
Almaral supports biotechnology advancement
Almaral (Almaral Ltd.) is a venture capital company that invests in early stage life science and biotechnology companies. Almaral provides financing and support to companies for expansion and development. The Almaral team also possesses extensive knowledge across various aspects of biotechnology.